Vanguard Group
EGRX

Vanguard Group’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Vanguard Group’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-579,507
Closed -$2.16M – 4380
2024
Q3 		$2.16M Buy
579,507
+15,111
+3% +$72.1K ﹤0.01% 3535
2024
Q2 		$3.16M Sell
564,396
-76,358
-12% -$333K ﹤0.01% 3421
2024
Q1 		$3.36M Buy
640,754
+2,630
+0.4% +$14.4K ﹤0.01% 3435
2023
Q4 		$3.34M Sell
638,124
-5,473
-0.9% -$54K ﹤0.01% 3428
2023
Q3 		$10.1M Buy
643,597
+21,911
+4% +$394K ﹤0.01% 2867
2023
Q2 		$12.1M Sell
621,686
-135,046
-18% -$3.2M ﹤0.01% 2833
2023
Q1 		$21.5M Sell
756,732
-7,075
-0.9% -$210K ﹤0.01% 2556
2022
Q4 		$22.3M Sell
763,807
-11,708
-2% -$372K ﹤0.01% 2572
2022
Q3 		$20.5M Buy
775,515
+3,756
+0.5% +$138K ﹤0.01% 2613
2022
Q2 		$34.3M Sell
771,759
-9,092
-1% -$418K ﹤0.01% 2374
2022
Q1 		$38.6M Buy
780,851
+20,383
+3% +$978K ﹤0.01% 2434
2021
Q4 		$38.7M Sell
760,468
-2,598
-0.3% -$135K ﹤0.01% 2493
2021
Q3 		$42.6M Buy
763,066
+9,786
+1% +$481K ﹤0.01% 2449
2021
Q2 		$32.2M Sell
753,280
-19,787
-3% -$817K ﹤0.01% 2592
2021
Q1 		$32.3M Buy
773,067
+8,132
+1% +$378K ﹤0.01% 2544
2020
Q4 		$35.6M Buy
764,935
+26,026
+4% +$1.22M ﹤0.01% 2370
2020
Q3 		$31.4M Buy
738,909
+5,965
+0.8% +$261K ﹤0.01% 2254
2020
Q2 		$35.2M Sell
732,944
-6,858
-0.9% -$342K ﹤0.01% 2178
2020
Q1 		$34M Sell
739,802
-20,568
-3% -$1.03M ﹤0.01% 2044
2019
Q4 		$45.7M Buy
760,370
+267
+0% +$15.9K ﹤0.01% 2155
2019
Q3 		$43M Buy
760,103
+6,629
+0.9% +$373K ﹤0.01% 2139
2019
Q2 		$42M Sell
753,474
-2,099
-0.3% -$109K ﹤0.01% 2193
2019
Q1 		$38.1M Buy
755,573
+27,164
+4% +$1.21M ﹤0.01% 2226
2018
Q4 		$29.3M Buy
728,409
+53,458
+8% +$2.75M ﹤0.01% 2271
2018
Q3 		$46.8M Buy
674,951
+59,474
+10% +$4.51M ﹤0.01% 2175
2018
Q2 		$46.6M Buy
615,477
+36,197
+6% +$2.28M ﹤0.01% 2162
2018
Q1 		$30.5M Buy
579,280
+9,486
+2% +$552K ﹤0.01% 2331
2017
Q4 		$30.4M Buy
569,794
+3,819
+0.7% +$213K ﹤0.01% 2312
2017
Q3 		$33.8M Buy
565,975
+4,155
+0.7% +$251K ﹤0.01% 2247
2017
Q2 		$44.3M Buy
561,820
+103,760
+23% +$8.49M ﹤0.01% 2069
2017
Q1 		$38M Buy
458,060
+29,339
+7% +$2.18M ﹤0.01% 2135
2016
Q4 		$34M Buy
428,721
+8,060
+2% +$585K ﹤0.01% 2159
2016
Q3 		$29.4M Buy
420,661
+58,052
+16% +$3.22M ﹤0.01% 2182
2016
Q2 		$14.1M Buy
362,609
+10,933
+3% +$455K ﹤0.01% 2487
2016
Q1 		$14.2M Sell
351,676
-6,997
-2% -$444K ﹤0.01% 2435
2015
Q4 		$31.8M Sell
358,673
-215,278
-38% -$17M ﹤0.01% 2104
2015
Q3 		$42.5M Buy
573,951
+258,554
+82% +$21.5M ﹤0.01% 1949
2015
Q2 		$25.5M Buy
315,397
+112,942
+56% +$7.36M ﹤0.01% 2249
2015
Q1 		$8.48M Buy
202,455
+167,513
+479% +$4.75M ﹤0.01% 2725
2014
Q4 		$542K Buy
34,942
+1,710
+5% +$21.8K ﹤0.01% 3702
2014
Q3 		$420K Buy
33,232
+20,980
+171% +$260K ﹤0.01% 3764
2014
Q2 		$176K Buy
+12,252
New +$140K ﹤0.01% 3871

Other funds holding EGRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
AIC
Archer Investment Corporation Carmel, Indiana $469M AUM 19.1% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Vanguard Group's EGRX Position: Q4 2024 in Review

Vanguard Group sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2024, closing a stake of 579,507 shares — an estimated $2.16M sold.

Vanguard Group first reported a position in EGRX in Q2 2014 and held it in 42 quarters. The position peaked at $46.8M in Q3 2018. 9 funds tracked by Wall St. Rank hold EGRX as of Q4 2024.

  • Vanguard Group reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2024 after selling out during the quarter.
  • Vanguard Group sold 579,507 Eagle Pharmaceuticals, Inc. shares in Q4 2024, an estimated $2.16M.
  • Vanguard Group first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2014 and held it in 42 quarters.
  • Vanguard Group's Eagle Pharmaceuticals, Inc. position peaked at $46.8M in Q3 2018.
  • 9 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2024.

Based on Vanguard Group's 13F filing for Q4 2024, filed 11 Feb 2025.